Brazil’s 4mg Pharmaceutical Model: What ANVISA’s Direction Could Mean for Innovation, Consumers, and Latin America’s Regulatory Future
Brazil is increasingly positioning itself as one of Latin America’s most consequential regulatory bellwethers in the debate over novel nicotine products. As policymakers across the region assess how emerging nicotine categories should be governed, Brazil’s pharmaceutical-style approach, centered around strict dosage controls such as a 4mg cap, signals a distinctly cautious pathway. For GINN LatAm,…